Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Neuroestimulación no invasiva como herramienta de diagnóstico y manejo de enfermedades neurodegenerativas

29 de septiembre de 2026 actualizado por: Eino Solje, Kuopio University Hospital

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Descripción general del estudio

Descripción detallada

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

200

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Eino Solje, MD, PhD
  • Número de teléfono: +358 17 713 311
  • Correo electrónico: eino.solje@uef.fi

Ubicaciones de estudio

      • Kuopio, Finlandia
        • Reclutamiento
        • Kuopio University Hospital
        • Contacto:
          • Eino Solje

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Mild Cognitive Impairment due to Alzheimer's disease
  • Dementia with Lewy Bodies
  • Frontotemporal dementia
  • Idiopathic normal pressure hydrocephalus (iNPH)

Exclusion Criteria:

  • History of seizures
  • Pregnancy
  • Metal implants in the head (except dental fillings)
  • Electronic implants (i.e. pace-maker, implanted medical pump)
  • Age <18 years

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Real tACS

Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)

Single session of gamma tACS (40 Hz) over the superior parietal cortex

Comparador de placebos: Sham tACS

Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus)

Single session of gamma tACS (40 Hz) over the superior parietal cortex

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Changes in Rey Auditory Verbal Learning Test score
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes.

The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance).

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
Changes in Rey Auditory Verbal Learning Test, recognition
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat.

After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance).

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
Changes in orientation to time and place (MMSE questions 1-10)
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance).

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
Changes in Trail Making A & B tests
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention

TMT A & B tests. Time to perform set is recorded.

Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
Changes in INECO Frontal Screening test
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention

Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance)

Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
Changes in phonemic fluency
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute.

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in SAI measurements
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in SICI measurements
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in ICF measurements
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in modified Frontal Behavioral Inventory (FBI-mod) score
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

The modified Frontal Behavioral Inventory (FBI-mod) is used to assess behavioral symptoms associated with frontotemporal dysfunction. The questionnaire evaluates changes in behavioral and personality features. Higher scores indicate a greater severity of behavioral symptoms.

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
Change in Neuropsychiatric Inventory (NPI) score
Periodo de tiempo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

The Neuropsychiatric Inventory (NPI) is used to assess neuropsychiatric symptoms, including their frequency and severity. Higher total scores indicate a greater burden of neuropsychiatric symptoms.

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Eino Solje, MD, PhD, Kuopio University Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de noviembre de 2022

Finalización primaria (Estimado)

1 de julio de 2032

Finalización del estudio (Estimado)

1 de julio de 2032

Fechas de registro del estudio

Enviado por primera vez

23 de marzo de 2022

Primero enviado que cumplió con los criterios de control de calidad

11 de abril de 2022

Publicado por primera vez (Actual)

14 de abril de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Pseudonymized data upon request, according to Finnish national and EU GDPR regulations

Marco de tiempo para compartir IPD

Data will be shared after the study completion indefinitely.

Criterios de acceso compartido de IPD

Reasonable request

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir